NCT04021329

Brief Summary

Post-Traumatic Stress Disorder(PTSD) develops after exposure to or witnessing traumatic events. PTSD is highly comorbid and individuals with PTSD usually report Major Depressive Disorder(MDD). Common treatment choices for PTSD and MDD are either EMDR or CBT, however, little is known about their comparative efficacy, especially in Pakistan. Therefore, this Randomized Controlled Trial(RCT) aims at determining the comparative efficacy of EMDR vs CBT in Pakistan. This study will also examine the association between reduction in symptoms of PTSD and MDD over course of treatment. In this regard, two arms Crossover Randomized Controlled Trial(RCT) with Repeated Measures Design will be selected. This study will be conducted at two rehabilitation centres and patients will be screened at Time:01, baseline; Time:02, during treatment; Time:03, post treatment and Time:04, 06 months follow-up. All analyses will be performed according to intention-to-treat principle. Variations in symptoms will be analysed by using descriptive statistics, χ2 tests, t-tests, and one way ANOVA. To examine changes in PTSD and MDD across time and to check efficacy of each treatment, a series of Linear Mixed Models will be run. Furthermore, a series of multi-level lagged mediation analysis will be performed to check bi-directional mediation between changes PTSD and MDD over time. This protocol has outlined the rationale for determining efficacy of EMDR and CBT in Pakistan. It will help in answering a broad range of questions concerning efficacy of newly developed evidence-based treatments. Moreover, it may also guide future research on the treatment of PTSD and MDD in the developing countries.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 11, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 16, 2019

Completed
1.2 years until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2021

Completed
Last Updated

February 2, 2023

Status Verified

February 1, 2023

Enrollment Period

10 months

First QC Date

July 11, 2019

Last Update Submit

February 1, 2023

Conditions

Keywords

Post-traumatic Stress Disorder, Major Depressive Disorder, Comorbidity, Eye Movement Desensitization & Reprocessing, Cognitive Behavioral Therapy

Outcome Measures

Primary Outcomes (2)

  • Measurement of Change in the symptoms of Post Traumatic Stress Disorder

    Clinician-Administered Post Traumatic Stress Disorder Scale-5 (Weathers, Blake, et al., 2013) These diagnostic tools will be used to assess the symptoms of Post Traumatic Stress Disorder. Any changes in the level of PTSD will be noted with respect to Pre, Mid and Post treatment stages The total symptom severity score is calculated by summing severity scores for the 20 * Criterion A (items 1-5); (Exposure to actual or threatened death) * Criterion B (items 6-7); (Presence of intrusion symptoms associated with the traumatic events) * Criterion C (items 8-14); (Persistent avoidance of stimuli associated with the traumatic events) * Criterion D (items 15-20). (Negative alterations in cognitions and mood associated with the traumatic events) Severity Rating 0. Absent: 1. Mild / subthreshold:. 2. Moderate / threshold: 3. Severe / markedly elevated: 4. Extreme / incapacitating:

    1st week (Baseline/pre-treatment screening, T-1); six weeks (during treatment screening, T-2); 12 weeks (post-treatment assessment, T-3). Finally, three months (follow up assessment, T-4).

  • Measurement of Socio Demographic Profile

    Socio-demographic characteristics of the patients, like age, gender, marital status, occupation and social background

    1st week at start of treatment, i.e, from date of randomization

Secondary Outcomes (1)

  • Measurement of Change in the symptoms of major depression

    1st week (Baseline/pre-treatment screening, T-1); six weeks (during treatment screening, T-2); 12 weeks (post-treatment assessment, T-3). Finally, three months (follow up assessment, T-4).

Study Arms (2)

EMDR Therapy

OTHER

One arm will be a group subjected to EMDR Therapy

Behavioral: CBT Therapy

CBT Therapy

OTHER

other arm will be a group subjected to CBT Therapy

Behavioral: CBT Therapy

Interventions

CBT TherapyBEHAVIORAL

information added previously

Also known as: EMDR Therapy
CBT TherapyEMDR Therapy

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may not qualify if:

  • The following patients will be excluded:
  • Patients below the age of 18 years and above 60 years as this study is not on children or older patients;
  • Patients who can't move their hands and eyes/or can't perform basic movements;
  • Patients who are unconscious for longer periods and unable to recover consciousness;
  • Patients not meeting the basic screening criteria of PTSD/ PTSD is not the main problem;
  • Patients with severe intellectual impairments, since such patients are difficult to communicate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Anwar Khan

Karak, KPK, 27200, Pakistan

Location

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticDepressive Disorder, Major

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental DisordersDepressive DisorderMood Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: The current study will be a two arms cross over Randomized Controlled Trial (RCT) with Repeated Measures. Moreover, the Consolidated Standards of Reporting Trials (CONSORT) group flow diagram and SPIRIT Checklist will be followed to carry out and report this study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 11, 2019

First Posted

July 16, 2019

Study Start

October 1, 2020

Primary Completion

August 1, 2021

Study Completion

October 1, 2021

Last Updated

February 2, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will share

the data obtained will be published in peer reviewed journals

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
it will available next year on line
Access Criteria
will be on-line accessible

Locations